Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma"

Biol Blood Marrow Transplant. 2020 Dec;26(12):e335-e336. doi: 10.1016/j.bbmt.2020.09.009. Epub 2020 Sep 18.

Authors

Olalekan O Oluwole¹, Jeroen P Jansen², Vincent W Lin³, Keith Chan⁴, Sam Keeping⁴, Lynn Navale³, Frederick L Locke⁵

Affiliations

¹ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. Electronic address: olalekan.oluwole@vumc.org.
² Precision HEOR, Oakland, California.
³ Kite Pharma, a Gilead Company, Santa Monica, California.
⁴ Precision HEOR, Vancouver, British Columbia, Canada.
⁵ Moffitt Cancer Center, Tampa, Florida.

PMID: 32950694
DOI: 10.1016/j.bbmt.2020.09.009

No abstract available

Publication types

Letter
Comment

MeSH terms

Antigens, CD19 / therapeutic use
Biological Products
Humans
Immunotherapy, Adoptive*
Lymphoma, B-Cell*
Receptors, Antigen, T-Cell

Substances

Antigens, CD19
Biological Products
Receptors, Antigen, T-Cell
tisagenlecleucel
axicabtagene ciloleucel